Zhao, Ruiyue http://orcid.org/0000-0001-5242-0785
Xia, Zeheng
Ke, Miao
Lv, Jie
Zhong, Huizhen
He, Yulu
Gu, Di
Liu, Yongda
Zeng, Guohua
Zhu, Lin
Alexoff, David
Kung, Hank F.
Wang, Xinlu
Sun, Tao
Funding for this research was provided by:
Guangdong regional joint fund (2022A1515110941)
Guangzhou basic and applied basic research (2023A04J1196)
Science and technology program of Guangzhou (202201020558)
Enhancing scientific research in Guangzhou Medical University
Cultivation Fund of the Key Scientific and Technical Innovation Project, Ministry of Education (GJJSTD20180002)
the Key Laboratory for Magnetic Resonance and Multimodality Imaging of Guangdong Province (2023B1212060052)
Shenzhen Science and Technology Innovation Committee (20220531100209020)
Department of Science and Technology of Guangdong Province (2022A1515110716)
Article History
Received: 19 October 2023
Accepted: 20 January 2024
First Online: 29 January 2024
Declarations
:
: This study was approved by the Clinical Research Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University (ES-2023-141), and it was conducted in accordance with the principles of the Declaration of Helsinki.
: Informed consent was obtained from all participants included in the study.
: David Alexoff and Hank F. Kung are employees of Five Eleven Pharma, and Hank Kung is also the founder and board of the company, which holds the patent rights for [<sup>18</sup>F]AlF-P16-093 and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.